Loading...

FITC anti-human CD45 Antibody

Pricing & Availability
Clone
HI30 (See other available formats)
Regulatory Status
RUO
Workshop
IV N816
Other Names
LCA, T200
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
Hi30
Human peripheral blood lymphocytes, monocytes and granulocytes stained with HI30 FITC
  • Hi30
    Human peripheral blood lymphocytes, monocytes and granulocytes stained with HI30 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
304005 25 tests 33 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304006 100 tests 72 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304054 100 µg 141 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304038 500 tests 325 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD45 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections9, inhibition of CD45 functions4, immunofluorescence11, Western blotting3, and spatial biology (IBEX)16,17.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, et al. 1993. Cell 74:143.
  3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
  4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
  5. Nagano M, et al. 2007. Blood 110:151.
  6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
  7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
  11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
  12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed
  15. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li Q, et al. 2019. Am J Transl Res. 10:4322. PubMed
  2. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  3. Mulay A, et al. 2021. Cell Reports. 35(5):109055. PubMed
  4. Lau D, et al. 2022. Nat Commun. 13:4053. PubMed
  5. Ducoli L, et al. 2021. Nat Commun. 12:925. PubMed
  6. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  7. Chang Y, et al. 2022. Cell Rep. 40:111128. PubMed
  8. Abe I, et al. 2022. Dev Cell. 57:2623. PubMed
  9. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  10. Tan D, et al. 2023. Front Oncol. 12:1043479. PubMed
  11. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  12. Calvanese V, et al. 2022. Nature. 604:534. PubMed
  13. Korsunsky I, et al. 2022. Med. 3:481. PubMed
  14. Zhu H, et al. 2022. Cell Transplant. 31:9636897221106996. PubMed
  15. González-Casimiro CM, et al. 2022. Int J Mol Sci. 23:. PubMed
  16. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  17. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  18. Liu RX, et al. 2023. iScience. 26:106140. PubMed
  19. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  20. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  21. Okano F, et al. 2023. Cancer Res Commun. 3:640. PubMed
  22. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  23. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  24. Zong D, et al. 2021. BMC Biol. 19:79. PubMed
  25. Jacoby E, et al. 2021. NPJ Regen Med. 6:58. PubMed
  26. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  27. Lim JT, et al. 2020. Mol Cancer Ther. 1809:19. PubMed
  28. Miedema A, et al. 2022. Acta Neuropathol Commun. 10:8. PubMed
  29. Gomzikova MO, et al. 2019. Cells. 0.440972222. PubMed
  30. Selich A, et al. 2019. Stem Cell Reports. 13:262. PubMed
  31. Sun Z, et al. 2022. Stem Cell Res Ther. 13:297. PubMed
  32. Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed
  33. Liu Z, et al. 2021. Molecules. 26:. PubMed
  34. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  35. Travaglini KJ, et al. 2020. Nature. 587:619. PubMed
  36. Grove K, et al. 2016. PLoS One. 11: 0145961. PubMed
  37. Skrbo N, et al. 2014. PLoS One. 9:113278. PubMed
  38. Wang D, et al. 2019. Cell Res. 29:832. PubMed
  39. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  40. Xia Y, et al. 2019. Gastroenterol Res Pract. 2019:5436961. PubMed
  41. Schulz A, et al. 2019. Cell Rep. 29:1074. PubMed
  42. Baccelli I, et al. 2020. Cancer Cell. 36(1):84-99. PubMed
  43. Chen P, et al. 2021. Front Immunol. 12:689019. PubMed
  44. Wu CL, et al. 2021. Nat Commun. 12:362. PubMed
  45. Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed
  46. Koide M, et al. 2018. Tohoku J Exp Med. 244:15:00. PubMed
  47. Yuan Z, et al. 2018. Emerg Microbes Infect. 7:59. PubMed
  48. Yan K, et al. 2022. iScience. 25:104822. PubMed
  49. Song M, et al. 2022. J Gene Med. 24:e3455. PubMed
  50. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  51. Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed
  52. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. PubMed
  53. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  54. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  55. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  56. Zhang B, et al. 2013. PLoS One. 8:57114. PubMed
  57. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  58. Ronaldson-Bouchard K, et al. 2022. Nat Biomed Eng. 6:351. PubMed
  59. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  60. Pabst C, et al. 2016. Blood. 127: 2018-2027. PubMed
  61. Wang L, et al. 2014. Proc Natl Acad Sci U S A. 111:3146. PubMed
  62. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
  63. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
  64. Lee HJ, et al. 2017. Oncotarget. 8:113345. PubMed
  65. Saunders L, et al. 2015. Sci Transl Med. 7: 302ra136. PubMed
  66. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  67. van Gastel N, et al. 2020. Cell Metabolism. 32(3):391-403.e6. PubMed
  68. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  69. Sicklinger F, et al. 2021. J Clin Invest. 131:. PubMed
  70. Okurut S, et al. 2020. Infect Immun. 88:. PubMed
  71. Saraiva L, et al. 2019. Cytometry B Clin Cytom. N/A. PubMed
  72. Hsieh J, et al. 2013. Nucleic Acids Res. 41:9753. PubMed
  73. Didigu C, et al. 2014. Blood. 123:61. PubMed
  74. Nano R, et al. 2022. STAR Protoc. 3:101354. PubMed
  75. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  76. Blomme EE, et al. 2021. Clin Transl Immunology. 10:e1287. PubMed
  77. He Y, et al. 2022. Cells. 11:. PubMed
  78. Ran Y, et al. 2022. Stem Cell Res Ther. 13:507. PubMed
  79. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  80. Labedz-Maslowska A, et al. 2020. Int J Mol Sci. 21:. PubMed
  81. Garrido-Martin EM, et al. 2020. J Immunother Cancer. 8:00. PubMed
  82. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  83. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  84. S Tzeng 2016. J Vis Exp. 118:e54582. PubMed
  85. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  86. Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed
  87. Yuan Z, et al. 2016. J Virol. 90: 7728 - 7739. PubMed
  88. Genbacev O, et al. 2016. Hum Reprod. 31: 1300 - 1314. PubMed
  89. Rousset F, et al. 2018. Mol Ther Nucleic Acids. 14:351. PubMed
  90. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  91. Wu SZ, et al. 2020. EMBO J. 39:e104063. PubMed
  92. Sun YF, et al. 2021. Nat Commun. 12:4091. PubMed
  93. Bailey AL, et al. 2020. bioRxiv. . PubMed
  94. Haynes BA, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2168. PubMed
  95. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  96. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  97. Niu C, et al. 2017. Mol Med Rep. 16:4879. PubMed
RRID
AB_2562050 (BioLegend Cat. No. 304005)
AB_2562050 (BioLegend Cat. No. 304006)
AB_2562050 (BioLegend Cat. No. 304054)
AB_2562050 (BioLegend Cat. No. 304038)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane protein, 180-240 kD (multiple isoforms)
Distribution

Hematopoietic cells, not expressed in circulating erythrocytes or platelets

Function
TCR and BCR mediated activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
Hematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References
  1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
  2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD45 HI30 FC
Biotin anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
PE/Cyanine5 anti-human CD45 HI30 FC
Purified anti-human CD45 HI30 FC,CyTOF®,IHC-P,WB,IHC-F,ICC
APC/Cyanine7 anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
Alexa Fluor® 488 anti-human CD45 HI30 FC
Alexa Fluor® 647 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
Alexa Fluor® 700 anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
PerCP/Cyanine5.5 anti-human CD45 HI30 FC,SB
Brilliant Violet 421™ anti-human CD45 HI30 FC
Brilliant Violet 570™ anti-human CD45 HI30 FC
Brilliant Violet 510™ anti-human CD45 HI30 FC
Brilliant Violet 605™ anti-human CD45 HI30 FC
Brilliant Violet 650™ anti-human CD45 HI30 FC
Purified anti-human CD45 (Maxpar® Ready) HI30 FC,CyTOF®
Brilliant Violet 785™ anti-human CD45 HI30 FC
Brilliant Violet 711™ anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
Alexa Fluor® 594 anti-human CD45 HI30 IHC-P,SB
APC/Fire™ 750 anti-human CD45 HI30 FC
Pacific Blue™ anti-human CD45 HI30 FC
APC anti-human CD45 HI30 FC
PE/Cyanine7 anti-human CD45 HI30 FC
PE/Dazzle™ 594 anti-human CD45 HI30 FC
TotalSeq™-A0391 anti-human CD45 HI30 PG
TotalSeq™-B0391 anti-human CD45 HI30 PG
TotalSeq™-C0391 anti-human CD45 HI30 PG
PerCP/Cyanine5.5 anti-human CD45 HI30 FC
APC/Fire™ 750 anti-human CD45 HI30 FC
PE/Fire™ 640 anti-human CD45 HI30 FC
APC/Fire™ 810 anti-human CD45 HI30 FC
Spark YG™ 570 anti-human CD45 HI30 IHC-P
PE/Fire™ 700 anti-human CD45 HI30 FC
FITC anti-human CD45 HI30 FC
PerCP anti-human CD45 HI30 FC
Alexa Fluor® 660 anti-human CD45 Antibody HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
Spark YG™ 593 anti-human CD45 HI30 FC
GMP APC/Fire™ 750 anti-human CD45 HI30 FC
Spark Violet™ 538 anti-human CD45 HI30 FC
GMP APC anti-human CD45 HI30 FC
Spark UV™ 387 anti-human CD45 HI30 FC
GMP Pacific Blue™ anti-human CD45 HI30 FC
GMP PerCP anti-human CD45 HI30 FC
GMP FITC anti-human CD45 HI30 FC
PE anti-human CD45 HI30 FC
GMP PE/Dazzle™ 594 anti-human CD45 HI30 FC
GMP PerCP/Cyanine5.5 anti-human CD45 HI30 FC
Spark Blue™ 515 anti-human CD45 HI30 FC
TotalSeq™-D0391 anti-human CD45 HI30 PG
GMP PE/Cyanine7 anti-human CD45 HI30 FC
Spark Violet™ 500 anti-human CD45 HI30 FC
GMP PE anti-human CD45 HI30 FC
PE/Fire™ 810 anti-human CD45 HI30 FC
Spark PLUS UV395™ anti-human CD45 HI30 FC
Spark NIR™ 685 anti-human CD45 HI30 FC
Spark Violet™ 423 anti-human CD45 HI30 FC
Go To Top Version: 4    Revision Date: 08.19.2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account